The packaging, batch number, tablet form and embossing matched exactly the genuine packets.
On June 6, 2017, Gilead Sciences has recalled the batch and further investigated the issue. On June 14, the results of laboratory analysis of Harvoni® 90 mg / 400 mg tablets (Batch 16SFC021D) were available and showed that the product was identical with the original product for the European market, except for the colour. Furthermore, it turned out that the product was not intended for the EU market but as access market product. It is more than likely that the product was repackaged, relabeled and is therefore considered a counterfeit product.The emergence of counterfeit Harvoni® in Germany follows reports of fakes in other countries in 2016. Over the past 18 months, regulators in Israel, Japan and Switzerland have discovered batches of fake Harvoni®. The plastic bottles found in Switzerland originate in India and were imported by a Swiss trading company. The tablets found in Switzerland, like those discovered in Germany, were white.
Batches discovered in Japan were more diverse. Some tablets were purple. Others were more oval in shape than the diamond-shaped tablets manufactured by Gilead. It is advised not to purchase the medicine from unknown sources or via the Internet.
The BfArM Germany is working closely with national authorities, with the European Medicines Agency EMA and with other European authorities to establish whether Harvoni® packets with counterfeit contents have been imported to other countries in Europe.
BfArM Press Release (in German)
EMA: Scientific Guidlines